Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys.

@article{Woodburn2008ChronicPS,
  title={Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys.},
  author={Kathryn W. Woodburn and Susan D. Wilson and Kei-Lai Fong and Peter J. Schatz and Thomas L. Ferrell and Charles B. Spainhour and Daniel M. Norton},
  journal={Haematologica},
  year={2008},
  volume={93 9},
  pages={1376-9}
}
Hematide is a synthetic peptide-based, pegylated erythropoiesis stimulating agent in clinical development for treatment of anemia. To support chronic clinical dosing requirements, a 9-month repeat dose IV monkey safety study was undertaken. Animals received 0, 0.2, 2 or 20 mg/kg hematide IV every three weeks for nine months followed by a 14-week recovery. Hematide administration was associated with time and dose-dependent polycythemia. Histological findings were related to exaggerated… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Treatment of erythropoietin antibody-mediated pure red cell aplasia with a novel synthetic peptide-based erythropoietin receptor agonist

  • IC Macdougall, N Casadevall, M Froissart, CA Johnson, RB Stead, A-M Duliege
  • J Am Soc Nephrol 2007;[Abstract SU-FC061]
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…